Circulating Tumor DNA Exposure in Peripheral Blood
NCT03517332 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 10000
Last updated 2018-11-20
Summary
This is a prospective, multi-center, blinded feasibility study. The objective of this study is to test the feasibility of the detection of tumor DNA of a variety of tumors in peripheral blood using a novel process for the detection of circulating tumor DNA (ctDNA).
Conditions
- Colorectal Cancer
- Pancreatic Adenocarcinoma
- Gastric Cancer
- Hepatocellular Carcinoma
- Non-small Cell Lung Cancer
- Bladder Cancer
- Melanoma
- Ovarian Cancer
- Adrenocortical Cancer
- Breast Cancer
- Other Cancer
Sponsors & Collaborators
-
Quantgene Inc.
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2015-01-01
- Primary Completion
- 2019-12-31
- Completion
- 2019-12-31
Countries
- United States
- Switzerland
Study Locations
More Related Trials
-
Ascertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial Cancers
NCT00579163 ·Status: ACTIVE_NOT_RECRUITING
-
Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
NCT04354064 ·Status: RECRUITING
-
A Study of the Role of Circulating Tumor DNA in Predicting the Likelihood of Organ Preservation After Clinical Complete Response to Neoadjuvant Therapy for Rectal Cancer
NCT03749083 ·Status: WITHDRAWN
-
Detection of Tumor DNA in Blood Samples From Patients With Early Stage Cancer and "Healthy Controls"
NCT03071809 ·Status: TERMINATED
-
Role of Circulating Tumor DNA (ctDNA) From LIquid Biopsy in Early Stage NSCLC Resected Lung Tumor Investigation
NCT03553550 ·Status: TERMINATED
-
Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow
NCT03551951 ·Status: RECRUITING
-
Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers
NCT02838836 ·Status: RECRUITING
-
Collection of Blood, Bone Marrow, Tumor, or Tissue Samples From Patients With Cancer to Study Drug Resistance
NCT00026663 ·Status: COMPLETED
-
Circulating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV Non-small Cell Lung Cancer
NCT02245100 ·Status: COMPLETED
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
NCT01441089 ·Status: RECRUITING
-
ctDNA in Subjects With Muscle-invasive Bladder Cancer Treated With Trimodality Therapy
NCT05630131 ·Status: COMPLETED
-
Feasibility Study of a Molecular Karyotype Using a Very High-throughput Sequencing Approach, the "Massive Parallel Sequencing" on Circulating Tumor DNA
NCT04104633 ·Status: COMPLETED ·Phase: NA
-
Improved Diagnosis of Ovarian Cancer by Use of Circulating Tumor DNA as a Biomarker
NCT05763511 ·Status: RECRUITING
-
Detecting Cancers Earlier Through Elective Plasma-based CancerSEEK Testing
NCT04213326 ·Status: COMPLETED
-
Use of Ctdna in Patients With Gastrointestinal Tract Tumors
NCT06202131 ·Status: RECRUITING
-
Circulating DNA in Surgically Treated NSCLC
NCT04037150 ·Status: UNKNOWN
-
ctDNA in Patients With Thyroid Nodules
NCT02778412 ·Status: TERMINATED
-
Clinical Utility of Circulating Tumor DNA in Gastro-Esophageal Cancer
NCT04576858 ·Status: UNKNOWN
-
Clinical Utility of Selected Circulating Tumor DNA Assays in Patients With Advanced Malignancy
NCT06290856 ·Status: TERMINATED
-
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
NCT03662204 ·Status: COMPLETED
-
ctDNA as a Biomarker for Treatment Response in HNSCC
NCT03540563 ·Status: COMPLETED ·Phase: NA
-
Cell-free DNA in Hereditary And High-Risk Malignancies 1
NCT04261972 ·Status: ACTIVE_NOT_RECRUITING
-
Plasma ctDNA Detection in Diagnosis of Epithelial Ovarian Cancer.
NCT03155451 ·Status: COMPLETED
-
Circulating Tumor DNA Study in Patients With Endometrial Cancer
NCT05955079 ·Status: RECRUITING
-
Plasma Circulating Deoxyribonucelic Acid (DNA) as a Response Marker
NCT00318604 ·Status: UNKNOWN